TY - JOUR
T1 - Cannabidiol Is a Novel Modulator of Bacterial Membrane Vesicles
AU - Kosgodage, Uchini S
AU - Matewele, Paul
AU - Awamaria, Brigitte
AU - Kraev, Igor
AU - Warde, Purva
AU - Mastroianni, Giulia
AU - Nunn, alistair
AU - Guy, Geoffrey
AU - Bell, Jimmy
AU - Inal, Jameel
AU - Lange, Sigrun
PY - 2019/9/10
Y1 - 2019/9/10
N2 - Membrane vesicles (MVs) released from bacteria participate in cell communication and host-pathogen interactions. Roles for MVs in antibiotic resistance are gaining increased attention and in this study we investigated if known anti-bacterial effects of cannabidiol (CBD), a phytocannabinoid from Cannabis sativa, could be in part attributed to effects on bacterial MV profile and MV release. We found that CBD is a strong inhibitor of MV release from Gram-negative bacteria (E. coli VCS257), while inhibitory effect on MV release from Gram-positive bacteria (S. aureus subsp. aureus Rosenbach) was negligible. When used in combination with selected antibiotics, CBD significantly increased the bactericidal action of several antibiotics in the Gram-negative bacteria. In addition, CBD increased antibiotic effects of kanamycin in the Gram-positive bacteria, without affecting MV release. CBD furthermore changed protein profiles of MVs released from E. coli after 1 h CBD treatment. Our findings indicate that CBD may pose as a putative adjuvant agent for tailored co-application with selected antibiotics, depending on bacterial species, to increase antibiotic activity, including via MV inhibition, and help reduce antibiotic resistance.
AB - Membrane vesicles (MVs) released from bacteria participate in cell communication and host-pathogen interactions. Roles for MVs in antibiotic resistance are gaining increased attention and in this study we investigated if known anti-bacterial effects of cannabidiol (CBD), a phytocannabinoid from Cannabis sativa, could be in part attributed to effects on bacterial MV profile and MV release. We found that CBD is a strong inhibitor of MV release from Gram-negative bacteria (E. coli VCS257), while inhibitory effect on MV release from Gram-positive bacteria (S. aureus subsp. aureus Rosenbach) was negligible. When used in combination with selected antibiotics, CBD significantly increased the bactericidal action of several antibiotics in the Gram-negative bacteria. In addition, CBD increased antibiotic effects of kanamycin in the Gram-positive bacteria, without affecting MV release. CBD furthermore changed protein profiles of MVs released from E. coli after 1 h CBD treatment. Our findings indicate that CBD may pose as a putative adjuvant agent for tailored co-application with selected antibiotics, depending on bacterial species, to increase antibiotic activity, including via MV inhibition, and help reduce antibiotic resistance.
KW - E. coli VCS257
KW - S. aureus subsp. aureus Rosenbach
KW - antibiotic resistance
KW - bacterial membrane vesicles (MVs)
KW - cannabidiol (CBD)
KW - gram-negative
KW - gram-positive
UR - http://www.scopus.com/inward/record.url?scp=85072623682&partnerID=8YFLogxK
U2 - 10.3389/fcimb.2019.00324
DO - 10.3389/fcimb.2019.00324
M3 - Article
SN - 2235-2988
VL - 9
SP - 1
EP - 13
JO - Frontiers Cellular and Infection Microbiology
JF - Frontiers Cellular and Infection Microbiology
M1 - 324
ER -